A potent non-nucleoside RSV L-protein polymerase inhibitor with EC50 of 0.01 uM and 1.3 uM for RSV A2 and RSV B-WST, respectively.

A potent HIV-1 integrase strand transfer inhibitor with IC50 of 33 nM, 9.5 nM, 40 nM, 20 nM and 237 nM for wt IN, IN Y143R, IN N155H, G118R and IN G140S-Q148H, respectively.

A potent HIV integrase strand transfer inhibitor (InSTIs) with IC50 of 8 nM in HIV replication assay.

A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively.

A novel small-molecule arenaviruse inhibitor that exhibits strong anti-LCMV activity (IC50<1 uM) without cell toxicity.

A novel potent, selective HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with EC50 of 1, 1.3, 2.8 and 11 nM for WT, K103N, Y181C and K103N/Y181C, respectively.

A novel orally bioavailable fungal beta-1,3-D glucan synthetase inhibitor against Candida species C. glabrata (MIC 0.03 to 0.25 ug/ml), C. parapsilosis (MIC 0.06 to 0.25 ug/ml).

A novel compound that disrupts the HIV-1 integrase LEDGF interaction.

A novel brain penetrant antiprion compound with EC50 of 57 nM, prevents both PrP(Sc) accumulation and astrocytic gliosis in the cerebrum.

A novel anti-TB agent that has an MIC range of 0.06-0.5 ug/mL..

A novel antiprion compound with EC50 of 68 nM, significantly increases monoglycosylated/diglycosylated PrPSc..

A highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively.

A first-in-class, small molecule protein-protein inhibitor of the interaction between the E1 and E2 proteins of HPV types 6 and 11.

A benzofuran class inhibitor of M. tuberculosis Pks13 (Polyketide Synthase 13).